NR3C1 and colorectal cancer: The particularly low rate of GR positivity in colorectal cancer (17.1%, including 14.5% with low level positivity) is in agreement with an earlier study reporting negative GR immunostaining in all 35 analyzed colorectal adenocarcinomas [41].